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Abstract 22 
Objective: To develop an alternative method for summing biologically effective doses of 23 
external beam radiotherapy (EBRT) with interstitial HDR brachytherapy (BT) boost in breast 24 
cancer. The total doses using EBRT boost will be compared with BT boost using our method. 25 
Methods: Twenty-four EBRT plus interstitial HDR BT plans were selected and additional 26 
plans using EBRT boost were created. The prescribed dose was 2.67/40.05 Gy to the whole 27 
breast and 4.75/14.25 Gy BT or 2.67/10.7 Gy EBRT to the boost PTV. EBRT and BT CT was 28 
registered twice: fitting the target volumes and then using the lung, and the most exposed 29 
volume of critical organs in BT were identified on EBRT CT images. The minimal dose of 30 
these from EBRT was summed with their BT dose, and these EQD2 doses were compared 31 
using BT vs. EBRT boost. This method was compared with uniform dose conception (UDC). 32 
Results: D90 of the boost PTV was significantly higher with BT than with EBRT boost: 67.1 33 
Gy vs. 56.7 Gy, p=0.0001. There was no significant difference in the dose of the non-target 34 
and contralateral breast using BT and EBRT boost. The D1 to skin, lung and D0.1 to heart were 35 
58.6 Gy vs. 66.7 Gy (p=0.0025), 32.6 Gy vs. 50.6 Gy (p=0.0002) and 52.2 Gy vs. 58.1 Gy 36 
(p=0.0009), while D0.1 to ribs was 44.3 Gy vs. 37.7 Gy (p=0.0062), respectively. UDC 37 
overestimates D1(lung) by 54% (p=0.0001), D1(ribs) by 28% (p=0.0003). 38 
Conclusions: Based on our biological dose summation method, total dose of the PTV in the 39 
breast is higher using BT boost, than with EBRT. BT boost yields lower skin, lung and heart 40 
doses, but higher dose to ribs. UDC overestimates lung and ribs dose. 41 
Keywords: breast cancer; dose summation; integrated biological doses; boost; interstitial 42 
brachytherapy 43 
44 
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Introduction 45 
The standard of care in the curative treatment of early-stage breast cancer is breast-conserving 46 
surgery and postoperative external beam radiotherapy (EBRT) to the whole breast [1-3].  47 
Since 67-100% of ipsilateral breast recurrences originate from the vicinity of the primary 48 
tumour site, dose escalation to the tumour bed has an essential role in the postoperative 49 
treatment [4]. Several randomized trials have confirmed that a local boost after the whole 50 
breast irradiation significantly decreased the local recurrence rate [4-7]. The most frequently 51 
used radiotherapy combination is whole breast EBRT with two tangential photon beams and 52 
image-guided interstitial brachytherapy (BT) or EBRT boost to the tumour bed [4-17]. This 53 
complex combined treatment requires reliable reporting of the dose received by the whole 54 
breast, the boost planning target volume (PTV) and the critical structures. 55 
 Modern high-dose-rate (HDR) interstitial BT boost approach results similar or more 56 
favourable local control rate than conventional EBRT boost, what is more, BT boost has been 57 
linked with lower incidence of late side effects [18-19]. Furthermore, the dose of the most 58 
exposed part of the organs at risk (OARs) correlates with normal tissue toxicity [20]. 59 
To report the dose-volume parameters properly, overall volumetric doses from 60 
external beam- and brachytherapy have to be integrated. As simple physical dose summation 61 
does not take into consideration the different biological effects, the equivalent dose given in 2 62 
Gy fractions (EQD2) has to be calculated [21,22]. The dose distribution of the EBRT is 63 
assumed to be completely uniform, so the whole breast and the nearest OARs, included in the 64 
fields, receive the entire prescribed dose. Then, this equivalent uniform dose is calculated for 65 
dose summation with BT doses (Uniform Dose Conception, UDC) [23]. On the other hand, 66 
this assumption can be correct only for those organs, which are in the used tangential fields. It  67 
is well known that the most exposed part of the OARs in the integrated plans is located in the 68 
same region that receives the largest dose from boost BT. Nevertheless, this 1 or 0.1 cm3 69 
volume is not always in the same location as the most exposed volume of EBRT [24]. So, 70 
simple DVH addition sums the dose of two different volumes. 71 
In previous investigations, authors did not consider the real biological dose of the PTV 72 
and the OARs in combined EBRT with BT or EBRT boost treatments. Terheyden et al. [25] 73 
used the above mentioned UDC method to estimate the doses from EBRT and applied relative 74 
physical BT doses only. Shahbazian et al. [26] compared interstitial BT versus EBRT using 75 
photon and electron beams for tumour bed boost in deeply seated tumours. Nevertheless, they 76 
calculated only the relative dose of the boost treatments, and they did not consider the total 77 
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dose of the combined therapy. There is no other study in the literature available, which deals 78 
with the biological summation of the dose in combined radiotherapy in early-stage breast 79 
cancer. 80 
In the effort to calculate the total biological dose of combined EBRT and BT boost, 81 
applying the linear-quadratic formula for a dose-volume parameter is not correct, because the 82 
EQD2 dose of a voxel is based on the α/β value and the physical dose in the given voxel. In 83 
this way, the quadratic behaviour of the biological dose can not be taken into consideration. 84 
The biological dose has to be calculated voxel-by-voxel in the same organ, but currently this 85 
feature is not available in any of the treatment planning systems. 86 
In the future, the deformable image registration (DIR) could be an appropriate method 87 
to integrate EBRT and BT doses both for the boost PTV and for the OARs, but at present, it 88 
results in significant errors, especially where the dose summation is sensitive due to the high 89 
dose gradient of BT. Beside the different breast and lung anatomy, the main problems are the 90 
plastic catheters in situ, which are not present on EBRT image data sets. 91 
We have developed an alternative dose summation method in combined radiotherapy 92 
of cervical and prostate cancer [27,28]. The aim of the present study is to develop an 93 
alternative method for summing the biologically effective doses of whole breast EBRT with 94 
interstitial HDR BT boost in breast cancer, and compare the results with the UDC method. 95 
Additionally, the EQD2 total doses of EBRT for the whole breast plus HDR BT or EBRT 96 
boost will also be compared using our dose summation method. 97 
Materials and methods 98 
External beam radiotherapy 99 
Twenty-four EBRT for the whole breast plus interstitial HDR BT boost plans of the 100 
recently treated patients with early-stage breast cancer were included for this study. The 101 
EBRT was performed in supine position, the patients were immobilized with an arm support 102 
system. The 40.05 Gy dose was delivered with two tangential 6 MV photon beams with 2.67 103 
Gy daily fractions in a TrueBeam linear accelerator (Varian Medical Systems, Palo Alto, 104 
USA). The dose was prescribed to 95% of the dose in the isocentre. Isocentre was located on 105 
the central axis CT slice in a midpoint between lung-chest wall interface and skin surface. 106 
Field-in-field technique was used to avoid dose heterogeneities in the breast. Eclipse 107 
v13.7 (Varian Medical Systems, Palo Alto, USA) treatment planning system was used. Based 108 
on our local IGRT protocol, CBCT verification was made before the first three fractions, then 109 
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the systematic error was calculated and corrected before the 4th fraction followed by weekly 110 
verification. For patients, whom BT is not accomplishable, EBRT boost is performed using 111 
a uniform CTVPTV expansion margin of 0.5 cm. Therefore, during treatment planning, 112 
an additional EBRT boost plan was created using two field-in-field conformal beams, 113 
where 10.7 Gy was prescribed to the PTV in 2.67 Gy daily fractions, according to the 114 
recent recommendations [29]. 115 
 Brachytherapy 116 
EBRT to whole breast was complemented with CT-guided interstitial multicatheter 117 
HDR BT boost 2 to 3 weeks after completing EBRT. Patients were treated with an 192Ir 118 
source with 370 GBq initial activity using afterloading technique. The implantations were 119 
performed under local anaesthesia. Preimplant CT simulation was performed with template on 120 
the breast to define the PTV according to the surgical clips in the tumour bed and plan the 121 
needle placement. The PTV (equal to the CTV) was defined as the excision cavity with a 122 
margin of 1 to 2 cm according to the surgical tumour-free margin in all main six directions. 123 
(The contouring protocol was the same as for EBRT boost.) Following preimplant simulation, 124 
9 to 22 plastic needles (median: 16) were inserted into the previously targeted area in a 125 
triangular setting using template guidance. After then, a postimplant CT scanning was made 126 
for planning purpose using the same Thorax-Mamma Hounsfield Unit set as in EBRT CT 127 
scan with 3 mm slice thickness. The active lengths in the catheters were selected in such a 128 
way that the extreme source dwell positions in each catheter were on or close to the surface of 129 
the PTV. HIPO (Hybrid Inverse Planning Optimization) method (Oncentra Brachy v4.5.3, 130 
Elekta Brachytherapy, Veendendaal, The Netherlands) was used to achieve the optimal dose 131 
distribution where the target volume coverage by the reference dose is at least 90%, while 132 
keeping the dose non-uniformity ratio (DNR) less than 0.35. The dosimetric assumptions 133 
were the following in HIPO preset: 100% minimal (weight: 75) and 150% maximal dose 134 
(weight: 25) to the CTV, 50% maximal dose (weight: 40) to the skin, 50% maximal dose 135 
(weight: 30) to the ribs and 120% maximal dose (weight: 5) to the normal tissue.  The 136 
prescribed dose was 14.25 Gy to the PTV in 3 fractions (MicroSelectron v3 afterloader, 137 
Elekta Brachytherapy, Veendendaal, The Netherlands). The detailed description of our 138 
treatment method can be found in previous publications [30-34]. The total treatment time of 139 
EBRT and BT was 4 weeks (25-28 days). In clinical routine, the UDC method was used to 140 
determine the dose constraints for boost PTV and OARs in BT implant and calculate their 141 
total doses. 142 
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Dose summation 143 
First, the treatment planning CT for EBRT was registered with the postimplant CT set of 144 
BT in the EBRT treatment planning system in every case. During the manual registration, the 145 
EBRT CT set was shifted and rotated to match the CTVs of BT and EBRT plans (Figure 1a). 146 
Then, another registration was made matching the lungs and ribs of BT and EBRT plans 147 
(Figure 1b), when the first registration was not appropriate for these OARs too. 148 
Then, the localisation of the most exposed part of the OARs in the sum of EBRT and BT 149 
plans was found. Based on the evaluation of the dose distributions of whole breast EBRT 150 
and BT boost treatments (Figure 2a), the most exposed part of the skin, ipsilateral lung and 151 
ribs is in the region where the dose maximum is in BT. So, the BT dose of the most exposed 1 152 
(D1) and 0.1 cm
3 (D0.1) from BT were visualized in the EBRT CTs, and the intersection of this 153 
isodose volumes and the given organ was created (Figure 2b). The minimal dose of this 154 
intersection was calculated in EBRT plans and summed with the dose of this volumes from 155 
BT using the linear-quadratic radiobiological model. In the case of the contralateral breast and 156 
heart, the most exposed part is in the region where the dose maximum is in EBRT, as the dose 157 
contribution from the EBRT part is higher than the dose from BT boost. For these organs, the 158 
most exposed 1 and 0.1 cm3 from EBRT were used with the same way. The α/β of breast 159 
tumour was assumed 4 Gy [29], while for OARs 3 Gy was used. The minimum dose delivered 160 
to 90% of the boost PTV (D90) was calculated in the EBRT and BT plans and these doses 161 
were summed using also the linear-quadratic model. 162 
Wilcoxon-matched pairs test (Statistica 12.5, StatSoft, Tulsa, OK, USA) was used to 163 
compare biological total doses of the combination of whole breast EBRT and BT or EBRT 164 
boost in the treatment of early-stage breast tumour. The comparison of our biological dose 165 
summation (BDS) and the conventional UDC method was also performed with this statistical 166 
test. 167 
Results 168 
EBRT with BT boost 169 
The mean volume of the boost CTV was 47.9 cm3 (14.3-85.1 cm3) in BT. The ratio of the 170 
boost CTV and the whole breast volume was 0.09 (0.03-0.21). Nine patients had tumour in 171 
her left breast and 11 patients in the right one. We found that EQD2 D90 of the boost PTV 172 
was 67.1 Gy (64.9-73.7 Gy) using EBRT for whole breast and BT boost. The EQD2 mean 173 
dose of the non-target breast was 45.5 Gy (45.4-45.6 Gy) on average. The D1 and D0.1 of 174 
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contralateral breast were 0.72 Gy (0.4-1.0 Gy) and 0.99 Gy (0.6-1.5 Gy). The D1 and D0.1 of 175 
skin were 58.6 Gy (47.2-79.9 Gy) and 65.8 Gy (49.2-85.6 Gy). The D1 and D0.1 of lung were 176 
32.6 Gy (15.7-46.2 Gy) and 35.3 Gy (17.2-48.5 Gy). The D1 and D0.1 of heart were 50.6 Gy 177 
(37.6-61.7 Gy) and 52.2 Gy (38.4-64.0 Gy). The D1 and D0.1 of ribs were 40.2 Gy (34.1-48.1 178 
Gy) and 44.3 Gy (40.0-53.0 Gy). 179 
 EBRT with EBRT boost 180 
In EBRT boost, the volume of the PTV is larger than in BT, it was 85.3 cm3 on 181 
average (range: 35.8-132.5 cm3), however, the volume of the CTV was practically the same, 182 
48.2 cm3 (15.2-85.9 cm3) and 47.9 cm3 (14.3-85.1 cm3) in EBRT and BT boost plans 183 
(p=0.1419). In comparison of BT and EBRT boost techniques, D90 of the boost PTV was 184 
significantly higher with BT than with EBRT: 67.1 Gy vs. 56.7 Gy, p=0.0001. There was no 185 
significant difference in the dose of the non-target and contralateral breast using BT and 186 
EBRT boost. The D1 to skin was 58.6 Gy (47.2-79.9 Gy) and 66.7 Gy (65.5-67.5 Gy), 187 
p=0.0025, the D1 to lung was 32.6 Gy (15.7-46.2 Gy) and 50.6 Gy (37.6-64.0), p=0.0002, D0.1 188 
to heart was 52.2 Gy (38.4-64.0 Gy) and 58.1 Gy (51.7-69.1 Gy), p=0.0009, while D0.1 to ribs 189 
was 44.3 Gy (40.0-53.0 Gy) and 37.7 Gy (26.6-60.5 Gy), p=0.0062, respectively (Figure 3). 190 
The detailed results can be found in Table 1. 191 
UDC-method 192 
Comparing our dose summation method to the conventional UDC in the case of 193 
combined EBRT with BT boost, we found that the UDC overestimates D1 of lung by 54% 194 
(p=0.0001), D1 of ribs by 28% (p=0.0003). The detailed results can be found in Table 2. 195 
Discussion 196 
Dose escalation has a fundamental role in the postoperative radiotherapy of early-stage breast 197 
cancer [4]. Presently, one of the best alternatives for boost is BT, however, a controversy still 198 
exists regarding the optimal technique. Traditionally, EBRT with electron or photon beams 199 
have been used to deliver the boost dose to the tumour bed [3]. Later, HDR BT has been also 200 
accepted as a safe alternative boost modality [4-17]. 201 
Poortmans et al. [18] have pointed out the favourable local control rate with BT boost 202 
compared to EBRT boost. They also showed the lower incidence of side effects with BT 203 
boost [18], what we confirmed in a previous study [19]. We also demonstrated the correlation 204 
between dose-volume parameters and side effects [20]. The volume of the PTV, the ratio of 205 
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the PTV and the whole breast, the volume irradiated at least the prescribed dose, the number 206 
of catheters and TRAK increase the risk of late side effects. The volume irradiated at least the 207 
150% of the prescribed dose causes more Grade I pain in the breast, while maximal dose of 208 
the skin increased the risk of Grade I hyperpigmentation. The EQD2 prescribed dose to the 209 
boost PTV with our fractionation scheme is 65.3 Gy using BT and 56.4 Gy with EBRT boost. 210 
Despite the fact, that BT irradiated the boost volume almost with 10 Gy more dose, than 211 
EBRT boost technique, at the same time dose to the OARs is reduced with BT. In our study, 212 
using EBRT with HDR BT boost doses to all OARs can be kept under the tolerance levels. 213 
The EQD2 D90 of the PTV was 67.1 Gy, while the mean dose of the non-target breast was 214 
45.5 Gy. The D1 and D0.1 of contralateral breast was negligible, 0.72 and 0.99 Gy. The D1 215 
dose of the skin was 58.6 Gy, 87% of the total dose of the PTV. The D1 dose to the lung was 216 
32.6 Gy on average, approximately the half of the prescribed dose, while the D1 of the ribs 217 
was 40.2 Gy in our study, in spite of that the PTV is very close to the ribs in the case of 218 
deeply seated tumours. D1 to heart was 50.6 Gy on average in the case of left sided tumours. 219 
 Notwithstanding, in EBRT boost larger target volume is used than in BT, the total 220 
dose to the PTV is 18% less in our patient cohort, D90 was 67.1 Gy using BT and 56.7 Gy 221 
with EBRT boost. There were no significant differences in the dose of non-target and 222 
contralateral breast between the two boost techniques. D1 dose to the skin and lung were 223 
smaller with 14% (8.1 Gy) and 55% (18 Gy) using BT, than with EBRT boost. D0.1 to heart 224 
was slightly higher with EBRT, than with BT boost (58.1 Gy vs. 52.2 Gy), but both doses are 225 
clinically acceptable. Only the dose to the ribs was higher with BT boost, D1 was higher with 226 
15% (5.2 Gy) than using EBRT boost. It has to be stated, that no ribs toxicity was detected in 227 
our study population. Terheyden et al. [25] concluded the same tendency in case of the OARs. 228 
They confirmed, that there is no difference between BT and EBRT boost for left-sided 229 
cancers regarding the dose to the heart, although they used physical maximal point doses in 230 
their study. Shahbazian et al. [26] also showed the reduced dose to OARs using BT instead of 231 
EBRT boost with photon or electron beams. However, they used only relative dose-volume 232 
parameters. The lower dose to the critical organs using BT boost can account for the less 233 
toxicity in the case of BT compared to EBRT boost. 234 
In previous publications authors used the recommended UDC method to estimate the 235 
total dose of the prostate and OARs in combined therapy and calculated the relative dose-236 
volume parameters only [25,26]. However, they did not consider the real biological doses. 237 
Since the most exposed part of the skin, lung and ribs is in the region where the dose 238 
maximum is in BT, and the most exposed part of the contralateral breast and heart is in the 239 
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region where the dose maximum is in EBRT, this most exposed 1 and 0.1 cm3 can be used for 240 
the calculation of the total biological dose. In this small volume, we can disregard the 241 
quadratic dependence. Thus, our dose summation method is simple, timesaving and more 242 
personalised than the UDC method. The only more precise method would be a pixel-by-pixel 243 
calculation of the biological dose in the same organ after a deformable registration of BT and 244 
EBRT image series, but no treatment planning systems provides this possibility at the 245 
moment. 246 
The effect of the dose summation technique on dose-volume parameters in combined 247 
EBRT and BT was also investigated in our study. The EQD2 D90 of the boost PTV was 0.7% 248 
higher in our BDS than the conventional UDC method, but this 0.5 Gy difference is clinically 249 
negligible. The mean dose to the non-target breast and the D1 to skin was practically 250 
equivalent in our BDS and the UDC method. Nevertheless, UDC overestimates the total D1 251 
dose to lung by 54% (17.5 Gy) and D1 dose to ribs by 2.5% (11.2 Gy) compared to BDS 252 
method. The cause may be the development of EBRT techniques, such as using field-in-field 253 
technique instead of wedges and image-guidance during dose delivery, resulting in decreased  254 
dose of critical structures. Accordingly, the potential advantage of the BDS method is that it 255 
considers the most exposed part of the OARs and thus sparing these parts from higher doses 256 
in EBRT before boost irradiation. On the whole, the dose to the OARs can be reduced using 257 
our alternative dose summation method, therefore the treatment related toxicity can be 258 
decreased. 259 
It has to be mentioned that this dose summation method can cause uncertainties 260 
too. The possible sources of error could be the subjectivity of the manual registration 261 
process, difference between the EBRT and the BT boost CTV and possible movement of 262 
the surgical clips in the tumour bed due to tissue necrosis. 263 
 This study is the starting point of the development of an algorithm for the summation 264 
of EBRT and BT biologically effective doses, which uses an artificial-intelligence-based DIR 265 
algorithm to match the critical anatomical structures in the two radiotherapy modalities. 266 
Further investigations are needed to assess whether our method predicts toxicity better than 267 
the recent UDC method. 268 
Conclusions 269 
Based on our biological dose summation method in EBRT for whole breast with interstitial 270 
HDR BT or EBRT boost treatment in early-stage breast cancer, total dose of the boost PTV is 271 
higher using BT boost, than EBRT. Following the recommended fractionation scheme, BT 272 
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boost yields lower skin, lung and heart doses, but higher dose to ribs. UDC overestimates lung 273 
and ribs dose compared to our method.  274 
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Tables: 378 
EQD2 EBRT + BT boost EBRT + EBRT boost **p-value 
D90 (Gy) 67.1 (64.9-73.7) 56.7 (55.3-58.4) 0.0001 
Dmean(non-target breast) (Gy) 45.5 (45.4-45.6) 47.0 (38.8-54.3) 0.1590 
D1(contralat breast) (Gy) 0.72 (0.4-1.0) 0.64 (0.1-1.0) 0.3787 
D0.1(contralat breast) (Gy) 0.99 (0.6-1.5) 1.1 (0.6-1.6) 0.3341 
D1(skin) (Gy) 58.6 (47.2-79.9) 66.7 (65.5-67.5) 0.0025 
D0.1(skin) (Gy) 65.8 (49.2-85.6) 67.4 (65.9-70.4) 0.5197 
D1(lung) (Gy) 32.6 (15.7-46.2) 50.6 (37.6-64.0) 0.0002 
D0.1(lung) (Gy) 35.3 (17.2-48.5) 52.2 (38.4-61.7) 0.0002 
*D1(heart) (Gy) 50.6 (37.6-61.7) 53.2 (51.0-55.5) 0.0765 
*D0.1(heart) (Gy) 52.2 (38.4-64.0) 58.1 (51.1-69.1) 0.0009 
D1(ribs) (Gy) 40.2 (34.1-48.1) 35.0 (20.0-57.3) 0.0642 
D0.1(ribs) (Gy) 44.3 (40.0-53.0) 37.7 (26.6-60.5) 0.0062 
Table 1. The EQD2 total doses of external beam radiation therapy plus interstitial HDR 379 
BT boost (EBRT + BT boost) and external beam radiation therapy plus external beam 380 
radiation therapy boost (EBRT + EBRT boost). D90: the minimum dose delivered to 381 
90% of the boost PTV (Gy), Dmean(non-target breast): the mean dose of non-target 382 
breast, D1(x), D0.1(x): the minimal dose of the most exposed 1 and 0.1 cm3 of ‘x’ organ at 383 
risk, where x are contralateral breast (contralat breast), skin, lung, heart and ribs. *Left 384 
sided tumours. **Wilcoxon-matched pairs test. 385 
  386 
16 
 
 387 
EQD2 BDS UDC *p-value 
D90 (Gy) 67.1 (64.9-73.7) 66.6 (65.3-72.2) 0.0386 
Dmean(non-target breast) (Gy) 45.5 (45.4-45.6) 45.5 (45.5-45.6) 0.7353 
D1(skin) (Gy) 58.6 (47.2-79.9) 57.7 (47.2-73.5) 0.3061 
D0.1(skin) (Gy) 65.8 (49.2-85.6) 63.5 (46.2-88.4) 0.0534 
D1(lung) (Gy) 32.6 (15.7-46.2) 50.1 (47.0-57.3) 0.0001 
D0.1(lung) (Gy) 35.3 (17.2-48.5) 51.1 (47.2-60.3) 0.0001 
D1(ribs) (Gy) 40.2 (34.1-48.1) 51.4 (47.0-61.6) 0.0001 
D0.1(ribs) (Gy) 44.3 (40.0-53.0) 53.5 (47.5-65.7) 0.0003 
Table 2. The EQD2 total doses of external beam radiation therapy plus interstitial HDR 388 
BT boost calculated by our biological dose summation (BDS) and the uniform dose 389 
conception (UDC) method. D90: the minimum dose delivered to 90% of the boost PTV 390 
(Gy), Dmean(non-target breast): the mean dose of non-target breast, D1(x), D0.1(x): the 391 
minimal dose of the most exposed 1 and 0.1 cm3 of ‘x’ organ at risk, where x are skin, 392 
lung and ribs. *Wilcoxon-matched pairs test. 393 
394 
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Figures: 395 
 396 
Figure 1. Registration of the EBRT and BT CT sets based on the CTVs (red and pink) 397 
(a,) and the lung contours (turquoise and blue) (b,) on an axial (top) and a sagittal 398 
(bottom) plane. 399 
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 401 
Figure 2a. Typical dose distribution of whole breast EBRT (left) and BT boost (right) in 402 
the axial slice where the most exposed 1 cm3 part of the lung (blue) is (CTV: red). 403 
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 404 
Figure 2b. The most exposed 1 cm3 part (yellow) of the lung (blue) in an axial slice of the 405 
EBRT CT. 406 
  407 
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 408 
Figure 3. The EQD2 total doses of external beam radiation therapy plus interstitial HDR 409 
BT boost (BT) and external beam radiation therapy plus external beam radiation 410 
therapy boost (EBRT). D90: the minimum dose delivered to 90% of the boost PTV (Gy), 411 
Dmean(NTB): the mean dose of non-target breast, D1(x), D0.1(x): the minimal dose of the 412 
most exposed 1 and 0.1 cm3 of ‘x’ organ at risk, where x are skin, lung and ribs. 413 
